Nurix Therapeutics vs ARS Pharmaceuticals
ARS Pharmaceuticals reported revenue of $84 million in fiscal 2025, about the same as Nurix Therapeutics' $84 million in fiscal 2025. Nurix Therapeutics' revenue grew 54.0% in its latest year, and ARS Pharmaceuticals' fell 5.5%. Nurix Therapeutics had an operating margin of -340.2%, against -212.9% at ARS Pharmaceuticals. Free cash flow was −$263 million at Nurix Therapeutics and −$171 million at ARS Pharmaceuticals. Their fiscal years end in different months (November 30 and December 31), so the periods don't line up exactly.
Side by side
| Nurix Therapeutics | ARS Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Nov 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $84M | $84M |
| Revenue growth | 54.0% | −5.5% |
| Revenue growth a year, last 5 years | 36.4% | — |
| Gross margin | — | — |
| Operating margin | −340.2% | −212.9% |
| Net margin | −314.9% | −203.2% |
| Free cash flow | −$263M | −$171M |
| Free cash flow margin | −313.7% | −203.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 29.1% | −3.7% |
| Last close | $13.60 | $3.36 |
| P/E at the last close | 5.9× | — |
| Insider trades, last 12 months | sold $4.2 million | sold $283,550 |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Nurix TherapeuticsARS Pharmaceuticals
Operating margin
Percent of revenue
Nurix TherapeuticsARS Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nurix TherapeuticsARS Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nurix Therapeutics and ARS Pharmaceuticals pages.